Stocks moved unevenly on Friday, with pronounced gains in some names set against steep drops in others. The list of top performers and laggards cut across market-cap categories - from mega-cap technology companies to smaller biomedical and industrial firms - producing a choppy trading landscape.
Mega-Cap Movers (Market Cap $200B+)
- Seagate Technology (STX): -8.55%
- Marvell Technology Group Ltd (MRVL); Marvell Technology declares $0.06 quarterly dividend: -5.31%
- Arista Networks (ANET): -4.96%
Large-Cap Stock Movers (Market Cap $10-$200B)
- Moderna (MRNA): +11.05%
- New Providence Acquisition Corp N (ASTS): +11.37%
- Servicenow Inc (NOW): +8.71%
- Applovin (APP): +7.78%
- FormFactor (FORM): -9.12%
Mid-Cap Stock Movers (Market Cap $2-$10B)
- Regencell Bioscience Holdings (RGC): -18.57%
- SNXX (SNXX): -16.54%
- Visteon (VC); Baird downgrades Visteon stock rating on execution risk concerns: -11.93%
- TransMedics Group Inc (TMDX): -13.35%
- Chime Financial (CHYM): +10.4%
- Diodes Inc (DIOD): -10.09%
- Dragoneer Growth Opp (CCC): +9.13%
- Guidewire Software Inc (GWRE): +9.9%
Small-Cap Stock Movers (Market Cap $300M-$2B)
- Omeros Corp (OMER); European regulator issues negative opinion on Omeros’ TA-TMA drug: -21.62%
- Apogee Enterprise (APOG); Apogee Enterprises beats estimates but guides below views: +16.03%
- Intec Pharma Ltd (INDP): +16.56%
- Hemab Therapeutics Holdings (COAG); Hemab announces clinical updates across bleeding disorder pipeline: +17.93%
- Galena Biopharma (SLS): +14.91%
- Legato Merger III (ENRD): +14.05%
- DSC Holdings ADR (DSC): -14.46%
Company-specific developments are highlighted in several of these moves. Marvell's stock moved lower even as the company declared a $0.06 quarterly dividend. Visteon shares fell after Baird lowered its rating, citing concerns about the company’s execution. Omeros dropped sharply following a negative opinion from a European regulator on the company’s TA-TMA drug. Apogee Enterprises posted stronger-than-expected results but fell short of guidance expectations, while Hemab announced clinical updates across its bleeding disorder pipeline that corresponded with a sizable share rise.
Overall, Friday’s action shows how discrete corporate announcements and analyst decisions continue to generate outsized intraday moves, particularly among names with concentrated news flow. Technology, biotechnology and select industrial and software stocks were among the most visibly impacted sectors.